These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 17055096)

  • 1. Relationship between clinical factors and the incidence of toxicity after intra-arterial chemoradiation for head and neck cancer.
    van den Broek GB; Balm AJ; van den Brekel MW; Hauptmann M; Schornagel JH; Rasch CR
    Radiother Oncol; 2006 Nov; 81(2):143-50. PubMed ID: 17055096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose superselective intra-arterial cisplatin and concomitant radiation (RADPLAT) for advanced head and neck cancer.
    Balm AJ; Rasch CR; Schornagel JH; Hilgers FJ; Keus RB; Schultze-Kool L; Ackerstaff AH; Busschers W; Tan IB
    Head Neck; 2004 Jun; 26(6):485-93. PubMed ID: 15162349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of treatment intensification on acute local toxicity during radiotherapy for head and neck cancer: prospective observational study validating CTCAE, version 3.0, scoring system.
    Palazzi M; Tomatis S; Orlandi E; Guzzo M; Sangalli C; Potepan P; Fantini S; Bergamini C; Gavazzi C; Licitra L; Scaramellini G; Cantu' G; Olmi P
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):330-7. PubMed ID: 17881148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiotherapy and concomitant intraarterial cisplatin (RADPLAT) for advanced squamous cell carcinomas of the head and neck.
    Rabbani A; Hinerman RW; Schmalfuss IM; Amdur RJ; Morris CG; Peters KR; Robbins KT; Mendenhall WM
    Am J Clin Oncol; 2007 Jun; 30(3):283-6. PubMed ID: 17551306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperfractionated, accelerated chemoradiation with concurrent mitomycin-C and cisplatin in locally advanced head and neck cancer, a phase I/II study.
    Hehr T; Classen J; Welz S; Ganswindt U; Scheithauer H; Koitschev A; Bamberg M; Budach W
    Radiother Oncol; 2006 Jul; 80(1):33-8. PubMed ID: 16875750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer.
    Guerrero Urbano T; Clark CH; Hansen VN; Adams EJ; A'Hern R; Miles EA; McNair H; Bidmead M; Warrington AP; Dearnaley DP; Harrington KJ; Nutting CM
    Radiother Oncol; 2007 Oct; 85(1):36-41. PubMed ID: 17709149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
    Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
    Stadler P; Putnik K; Kreimeyer T; Sprague LD; Koelbl O; Schäfer C
    BMC Cancer; 2006 Dec; 6():279. PubMed ID: 17150114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma.
    Cerchietti LC; Navigante AH; Bonomi MR; Zaderajko MA; Menéndez PR; Pogany CE; Roth BM
    Cancer; 2002 Nov; 95(10):2230-6. PubMed ID: 12412178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-year quality of life assessment of an intra-arterial (RADPLAT) versus intravenous chemoradiation phase III trial.
    Ackerstaff AH; Balm AJ; Rasch CR; de Boer JP; Wiggenraad R; Rietveld DH; Gregor RT; Kröger R; Hilgers FJ
    Head Neck; 2009 Jan; 31(1):77-84. PubMed ID: 18972429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
    Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
    J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of prophylactic gastrostomy tubes for head and neck cancer patients undergoing chemoradiation.
    Nguyen NP; North D; Smith HJ; Dutta S; Alfieri A; Karlsson U; Lee H; Martinez T; Lemanski C; Nguyen LM; Ludin A; Sallah S
    Surg Oncol; 2006 Dec; 15(4):199-203. PubMed ID: 17280829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors predictive of local disease control after intra-arterial concomitant chemoradiation (RADPLAT).
    Robbins KT; Doweck I; Samant S; Vieira F; Kumar P
    Laryngoscope; 2004 Mar; 114(3):411-7. PubMed ID: 15091211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid superselective high-dose cisplatin infusion with concomitant radiotherapy for advanced head and neck cancer.
    Homma A; Furuta Y; Suzuki F; Oridate N; Hatakeyama H; Nagahashi T; Ushikoshi S; Asano T; Nishioka T; Shirato H; Fukuda S
    Head Neck; 2005 Jan; 27(1):65-71. PubMed ID: 15459915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the role of prophylactic gastrostomy tube placement prior to definitive chemoradiotherapy for head and neck cancer.
    Chen AM; Li BQ; Lau DH; Farwell DG; Luu Q; Stuart K; Newman K; Purdy JA; Vijayakumar S
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1026-32. PubMed ID: 20231073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.
    Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Rasch CR; Schornagel JH; Dreschler WA; Balm AJ
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1320-5. PubMed ID: 17418969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspiration rate following chemoradiation for head and neck cancer: an underreported occurrence.
    Nguyen NP; Frank C; Moltz CC; Vos P; Smith HJ; Bhamidipati PV; Karlsson U; Nguyen PD; Alfieri A; Nguyen LM; Lemanski C; Chan W; Rose S; Sallah S
    Radiother Oncol; 2006 Sep; 80(3):302-6. PubMed ID: 16890314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer.
    Caudell JJ; Schaner PE; Meredith RF; Locher JL; Nabell LM; Carroll WR; Magnuson JS; Spencer SA; Bonner JA
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):410-5. PubMed ID: 18635320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
    Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of tumor board recommendations on treatment outcome for locally advanced head and neck cancer.
    Nguyen NP; Vos P; Lee H; Borok TL; Karlsson U; Martinez T; Welsh J; Cohen D; Hamilton R; Nguyen N; Nguyen LM; Vinh-Hung V
    Oncology; 2008; 75(3-4):186-91. PubMed ID: 18841033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.